A Sulfur Containing Melanogenesis Substrate, N -Pr-4- S -CAP as a Potential Source for Selective Chemoimmunotherapy of Malignant Melanoma.

-propionyl-4--cysteaminylphenol (-Pr-4--CAP) is a substrate for tyrosinase, which is a melanin biosynthesis enzyme and has been shown to be selectively incorporated into melanoma cells. It was found to cause selective cytotoxicity against melanocytes and melanoma cells after selective incorporation, resulting in the induction of anti-melanoma immunity. However, the underlying mechanisms for the induction of anti-melanoma immunity remain unclear. This study aimed to elucidate the cellular mechanism for the induction of anti-melanoma immunity and clarify whether -Pr-4--CAP administration could be a new immunotherapeutic approach against melanoma, including local recurrence and distant metastasis. A T cell depletion assay was used for the identification of the effector cells responsible for -Pr-4--CAP-mediated anti-melanoma immunity. A cross-presentation assay was carried out by using -Pr-4--CAP-treated B16-OVA melanoma-loaded bone marrow-derived dendritic cells (BMDCs) and OVA-specific T cells. Administration of -Pr-4--CAP induced CD8 T cell-dependent anti-melanoma immunity and inhibited the growth of challenged B16F1 melanoma cells, indicating that the administration of -Pr-4--CAP can be a prophylactic therapy against recurrence and metastasis of melanoma. Moreover, intratumoral injection of -Pr-4--CAP in combination with BMDCs augmented the tumor growth inhibition when compared with administration of -Pr-4--CAP alone. BMDCs cross-presented a melanoma-specific antigen to CD8 T cells through -Pr-4--CAP-mediated melanoma cell death. Combination therapy using -Pr-4--CAP and BMDCs elicited a superior anti-melanoma effect. These results suggest that the administration of -Pr-4--CAP could be a new strategy for the prevention of local recurrence and distant metastasis of melanoma.